Drugs / Investigational COVID-19 Vaccine
Investigational COVID-19 Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06821061 | Feb → Dec 2025 | COVID-19, influenza | BioNTech SE | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-12-14 | BioNTech SE | Results Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2 biontech.com ↗
The study results demonstrate that BNT162b2 elicits a combined adaptive humoral and cellular immune response against SARS-CoV-2 and provide insights into the composite nature of BNT162b2-induced T cell immunity. |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Investigational COVID-19 Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06821061 ↗ |
| Modality | Messenger RNA (mRNA) | “modified RNA vaccine candidates against influenza and COVID-19” NCT06821061 ↗ |